Spero Therapeutics (SPRO) Stock Price, Quote, News & History | Benzinga

Spero Therapeutics Inc (SPRO) Stock Price, Quote, News & History

SPRONASDAQ

Trade with Public

Trade with Public

$1.23

0.0151.23%

At close: Aug 25, 5:00 PM EST

$1.23

N/A

After Hours: 8:51 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.23

Close

$1.23

Volume / Avg.

645.54K / 1.57M

Day Range

$1.20 - $1.26

52 Wk Range

1.08 - 3.08

Market Cap

$71.63M

P/E Ratio

8.68

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

3.13%

Days to Cover

1

Recent Spero Therapeutics, Inc. News

Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.

Avi Kapoor

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.

Vandana Singh

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Avi Kapoor

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga Senior Editor

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

19.58M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

-

Free Cash Flow (TTM)

19.58M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

19.58M

Analyst Rating and Forecast

2.0

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$22.02M

PE Ratio (TTM)

8.68

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.70

PB Ratio (TTM)

1.60

Earnings Yield % (TTM)

11.52%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

3.33

Price / EBITDA (TTM)

11.03

Price / Free Cash Flow (TTM)

3.72

Book Value / Share

$0.76

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$50.77M

Debt to Equity

0.05

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.23

Close

$1.23

Volume / Avg.

645.54K / 1.57M

Day Range

$1.20 - $1.26

52 Wk Range

1.08 - 3.08

Market Cap

$71.63M

P/E Ratio

8.68

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

3.13%

Days to Cover

1

About

Sector

Health Care

Industry

Biotechnology

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, teb...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Spero Therapeutics (SPRO) stock?

A

You can purchase shares of Spero Therapeutics (NASDAQ:SPRO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Spero Therapeutics (SPRO) competitors?

A

Other companies in Spero Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Spero Therapeutics (SPRO) stock?

A

Spero Therapeutics has a consensus price target of $5.00.

Q

What is the current price for Spero Therapeutics (SPRO)?

A

The stock price for Spero Therapeutics (NASDAQ: SPRO) is $1.23 last updated August 25, 2026 at 8:51 AM EDT.

Q

Does Spero Therapeutics (SPRO) pay a dividend?

A

There are no upcoming dividends for Spero Therapeutics.

Q

When is Spero Therapeutics (NASDAQ:SPRO) reporting earnings?

A

Spero Therapeutics does not have any upcoming earnings scheduled.

Q

Is Spero Therapeutics (SPRO) going to split?

A

There is no upcoming split for Spero Therapeutics.

Q

What sector and industry does Spero Therapeutics (SPRO) operate in?

A

Spero Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.